The Pain Signal That Won’t Shut Off

Via The Wellness Company

The Ache That Won’t Clock Out​


Chronic pain isn’t slowing down. It’s spreading.

New CDC data shows 24.3% of U.S. adults now live with chronic pain, up from 20.4% just a few years earlier. That’s a 19% jump, and it means nearly 1 in 4 adults deal with pain most days or every day.


Chronic pain is also one of the most common reasons adults seek medical care, and it only climbs with age.

So why are so many people still hurting?

For many, the source runs deeper than sore joints or a bad back. Chronic inflammation and an overactive immune system can keep your body’s pain signals switched on, along with the fatigue, brain fog, and stubborn weight that often come with them.

Covering the ache day after day never reaches where it starts.

Small Dose, Serious Relief​


Meet Low Dose Naltrexone (LDN), a prescription option used in wellness protocols since 1985 to target chronic inflammation at its source.

At very low doses, LDN briefly blocks certain receptors on immune cells. That signals your body to make more of its own natural endorphins, your built-in comfort chemicals, while helping calm an overactive immune response over time.

Why people are making the switch:

    • Reduces inflammation linked to pain and weight gain
    • Increases natural endorphins, which may improve energy, mood, and mental clarity
    • May reduce inflammation in the brain tied to fatigue and cognitive decline
    • Non-habit forming and designed for long-term use

Many people feel benefits within 4–8 weeks, with stronger results over months of steady use.

Your dose is personalized by a licensed provider, dispensed by a licensed U.S. pharmacy, and shipped free to your door.

Save 20% off Low Dose Naltrexone when you subscribe & save using code LDN20 at checkout.**

Tweet

Continue reading...

[ H/T The Burning Platform ]
  • Reading time 1 min read
  • Views1
  • Reading time 39 min read
  • Reading time 1 min read
  • Reading time 1 min read
  • Views1
  • Reading time 3 min read
  • Reading time 9 min read

Comments

There are no comments to display
Back
Top